Expresion of cell adhesion molecule CD44 in primary tumors of the liver: An immunohistochemical study

Liver

Volumn 17, Issue 1, 1997, Pages 17-23

  Washington, Kay ^a,b   Telen, Marilyn J ^a   Gottfried, Marcia R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carcinoma; CD44; Cholangiocarcinoma; Hepatocellular

Indexed keywords

CELL ADHESION MOLECULE; HERMES ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CLINICAL ARTICLE; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER ADENOMA; LIVER CELL; LIVER CELL CARCINOMA; LIVER SINUSOID; LIVER TUMOR; METASTASIS; NODULAR HYPERPLASIA; PROTEIN EXPRESSION; STAINING; SURVIVAL; TUMOR DIFFERENTIATION; BILE DUCT TUMOR; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY;

ADENOMA, LIVER CELL; ANTIGENS, CD44; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS;

EID: 0030615057     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0676.1997.tb00773.x     Document Type: Article

References (34)

1. AZNAVOORIAN S, MURPHY A N, STETLER-STEVENSON W G, LIOTTA L A. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993: 71: 1368-1379.
2. JALKANEN S, JOENSUU H, SODERSTROM K O, KLEMI P. Lymphocyte homing and clinical behaviour of non-Hodgkin's lymphoma. J Clin Invest 1991: 87: 1835-1840.
3. PENNEYS N S, SHAPIRO S. CD44 expression in Merkel cell carcinoma may correlate with risk of metastasis. J Cutan Pathol 1994: 21: 22-26.
4. GUNTHERT U, HOFMANN M, RUDY W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells Cell 1991: 65: 13-24.
5. SEITER S, ARCH R, REBER S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993: 177: 443-455.
6. HORST E, MEIJER C J L M, RADASZKIEWICZ T, OSSEKOPPELE GJ, VAN KRIEKEN J H J M, PALS S T. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990: 4: 595-599.
7. WASHINGTON K, GOTTFRIED M R, TELEN M J. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol 1994: 25: 1043-1049.
8. JOENSUU H, KLEMI P, TOIKKANEN S, JALKANEN S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993: 143: 867-874.
9. PICKER L J, NAKACHE M, BUTCHER E C. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol 1989: 109: 927-937.
10. HAYNES B F, TELEN M J, HALE L P, DENNING S M. CD44 - a molecule involved in leukocyte adherence and T cell activation. Immunol Today 1989: 10: 423-428.
11. MIYAKE K, UNDERHILL C B, LESLEY J, KINCADE P W. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 1990: 172: 69-75.
12. SCREATON G R, BELL M V, JACKSON D G, CORNELIS F B, GERTH U, BELL J I. Genomic structuring of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992: 89: 12160-12164.
13. MACKAY C R, TERPE H-J, STAUDER R, MARSTON W L, STARKE H, GUNTHERT U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biop 1994: 124: 71-82.
14. ARUFFO A, STAMENKOVIC I, MELNICK M, UNDERHILLL C B, SEE B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990: 61: 1303-1313.
15. MATSUMURA Y, TARIN D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992: 340: 1053-1058.
16. TELEN, M J, SHEHATA H, HAYNES B F. Human medullary thymocyte p80 antigen and In(lu) related p80 antigen reside on the same protein. Hum Immunol 1986: 17: 311-324.
17. HARN H-J, HO L-I, YU C-P, et al. The variant mRNA soform of human metastasis gene (CD44v) detected in the cell lines of human hepatocellular carcinoma. Biochem Mol Biol Int 1994: 32: 233-238.
18. VOLPES R, VAN DEN OORD J J, DESMET V J. Vascular adhesion molecules in acute and chronic liver inflammation. Hepatology 1992: 15: 269-275.
19. EDMONDSON H A, STEINER P E. Primary carcinoma of the liver. Cancer 1954: 7: 462-503.
20. BRIGATI D J, BUDGEON L R, UNGER E R, et al. Immuocytochemistry is automated: development of a robotic workstation based upon the capillary action principle. J Histotechnol 1988: 11: 165-183.
21. AMERICAN JOINT COMMITTEE FOR CANCER STAGING AND END-RESULTS REPORTING. Manual for staging cancer, 3rd edn. Philadelphia: JB Lippincott Co, 1988.
22. FUJITA N, YAEGASHI N, IDE Y, et al. Expression of CD44 in normal human versus tumor endometrial tissues: possible implications of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 1994: 54: 3922-3928.
23. JACKSON D G, SCHENKER T, WAIBEL R, BELL J I, STAHEL R A. Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer Suppl 1994: 8: 110-115
24. CANNISTRA S A, KANSAS G S, NILOFF J, DEFRANZO B, KIM Y, OTTENSMEIER C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partially mediated by CD44H. Cancer Res 1993: 53: 3820-3838.
25. PENNO M B, AUGUST J T, BAYLIN S B, et al. Expression of CD44 in human lung tumors. Cancer Res 1994: 54: 1381-1387.
26. HEIDER K H, DAMMRICH J, SKROCH-ANGEL P, et al. Differential expression of CD44 splice variants in intestinal and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993: 53: 4197-4203.
27. CHAUDRY A, GOBL A, ERICKSSON B, SKOGSEID B, OBERG K. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res 1994: 54: 981-986.
28. SHTIVELMAN E, BISHOP J M. Expression of CD44 is repressed in neuroblastoma cells. Mol Cellular Biol 1991: 11: 5446-5453.
29. KIM H, YANG X-L, ROSADA C, HAMILTON S R, AUGUST J T. CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation. Arch Biochem Biophys 1994: 310:504-507.
30. OGATA N, KAMIMURA T, ASKURA H Point mutation, allelic loss, and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 1991: 13: 31-37.
31. TADA M, OMATA M, OHTO M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 1991: 50: 1121-1124.
32. TSUDA H, HIROHASHI S, SHIMOSTAO Y, INO Y, YOSHIDA T, TERADA M. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989: 80: 196-199.
33. TADA M, OMATA M, OHTO M High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Canter 1992: 69: 1115-1118.
34. OHASHI K, TSUTSUMI M, et al. High rates of Ki-ras point mutation in both intra-and extra-hepatic cholangiocarcinomas. Jap J Clin Oncol 1994: 24: 305-310.